Opus Genetics, Inc. (IRD) vs Kyverna Therapeutics, Inc. (KYTX)

A side-by-side comparison of Opus Genetics, Inc. and Kyverna Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Opus Genetics, Inc. logo
IRD
Opus Genetics, Inc.
$356M
$4.31HealthcareDelayed quote: Oct 6, 2026, 11:10 AM EDT
Kyverna Therapeutics, Inc. logo
KYTX
Kyverna Therapeutics, Inc.
$388M
$6.39HealthcareDelayed quote: Oct 6, 2026, 11:10 AM EDT

Total return — IRD vs KYTX

growth of $100 · dividends reinvested · last 2y
IRD +239.5% (+84.3%/yr)KYTX +20.6% (+9.8%/yr)IRD compounded faster over this window
100200300400500Start $10020252026$340$121
IRD KYTX

IRD vs KYTX: by the numbers

  • •KYTX is the larger company ($388M vs $356M market cap).
  • •Both run net losses; KYTX's is the smaller (0.00% vs -1091.82% net margin).

Metrics side by side

Valuation

MetricIRDKYTX
P/S ratio36.14N/A
P/B ratioN/A2.35

Profitability

MetricIRDKYTX
Gross margin99.87%0.00%
Operating margin-271.90%0.00%
Net margin-1091.82%0.00%
ROEN/A-92.20%
ROIC-59.29%-80.67%

Growth (annualized)

MetricIRDKYTX
Revenue CAGR (5Y)150.49%N/A

Go deeper

Full IRD analysisFull KYTX analysisInteractive comparison tool

Dig into the metrics

Opus Genetics ROEKyverna Therapeutics ROEOpus Genetics operating marginKyverna Therapeutics operating marginOpus Genetics revenue growthKyverna Therapeutics revenue growthOpus Genetics free cash flowKyverna Therapeutics free cash flow

Opus Genetics & Kyverna Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.